A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome.

Abstract

We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred in the 10 patients.

• Authors: P Brown, P D Thompson, J C Rothwell, B L Day, C D Marsden
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 6 Issue 1 Pg. 73-5 ( 1991) ISSN: 0885-3185 [Print] United States
• PMID: 2005926 (Publication Type: Journal Article)

Chemical References

• Acetamides
• Anticonvulsants
• Monoamine Oxidase Inhibitors
• milacemide

Topics

• Acetamides (therapeutic use)
• Adult
• Aged
• Anticonvulsants
• Female
• Humans
• Male
• Middle Aged
• Monoamine Oxidase Inhibitors
• Muscle Rigidity (drug therapy)
• Myoclonus (drug therapy)
• Neurologic Examination
• Spasm (drug therapy)
• Syndrome